The New England journal of medicine, 2024-02, Vol.390 (6), p.497-509
- Harrison, Stephen A.
- Bedossa, Pierre
- Guy, Cynthia D.
- Schattenberg, Jörn M.
- Loomba, Rohit
- Taub, Rebecca
- Labriola, Dominic
- Moussa, Sam E.
- Neff, Guy W.
- Rinella, Mary E.
- Anstee, Quentin M.
- Abdelmalek, Manal F.
- Younossi, Zobair
- Baum, Seth J.
- Francque, Sven
- Charlton, Michael R.
- Newsome, Philip N.
- Lanthier, Nicolas
- Schiefke, Ingolf
- Mangia, Alessandra
- Pericàs, Juan M.
- Patil, Rashmee
- Sanyal, Arun J.
- Noureddin, Mazen
- Bansal, Meena B.
- Alkhouri, Naim
- Castera, Laurent
- Rudraraju, Madhavi
- Ratziu, Vlad
2024
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Harrison, Stephen A.
- Bedossa, Pierre
- Guy, Cynthia D.
- Schattenberg, Jörn M.
- Loomba, Rohit
- Taub, Rebecca
- Labriola, Dominic
- Moussa, Sam E.
- Neff, Guy W.
- Rinella, Mary E.
- Anstee, Quentin M.
- Abdelmalek, Manal F.
- Younossi, Zobair
- Baum, Seth J.
- Francque, Sven
- Charlton, Michael R.
- Newsome, Philip N.
- Lanthier, Nicolas
- Schiefke, Ingolf
- Mangia, Alessandra
- Pericàs, Juan M.
- Patil, Rashmee
- Sanyal, Arun J.
- Noureddin, Mazen
- Bansal, Meena B.
- Alkhouri, Naim
- Castera, Laurent
- Rudraraju, Madhavi
- Ratziu, Vlad
- Titel
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
- Ist Teil von
- The New England journal of medicine, 2024-02, Vol.390 (6), p.497-509
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2024
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Resmetirom is a selective agonist of THR-β. In adults with nonalcoholic steatohepatitis and fibrosis, daily resmetirom (80 mg or 100 mg) was superior to placebo with respect to NASH resolution and fibrosis improvement.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2309000Titel-ID: cdi_hal_primary_oai_HAL_hal_04522712v1
- Format
- –
- Schlagworte
- Adult, Biopsy, Cholesterol, Cirrhosis, Clinical outcomes, Diabetes, Diarrhea, Dose-Response Relationship, Drug, Double-Blind Method, Drug dosages, Endocrinology, Endocrinology General, Fatty liver, FDA approval, Fibrosis, Gastroenterology, Gastroenterology General, Human health and pathology, Humans, Inflammation, Life Sciences, Liver - diagnostic imaging, Liver - drug effects, Liver - pathology, Liver cirrhosis, Liver Cirrhosis - drug therapy, Liver Cirrhosis - etiology, Liver Cirrhosis - pathology, Liver Disease, Liver diseases, Metabolism, Non-alcoholic Fatty Liver Disease - complications, Non-alcoholic Fatty Liver Disease - drug therapy, Non-alcoholic Fatty Liver Disease - pathology, Patients, Placebos, Pyridazines - therapeutic use, Research centers, Thyroid Hormone Receptors beta - agonists, Treatment Outcome, Uracil - analogs & derivatives